title: [Fluoroscopic contrast medium percutaneous ethanol injection therapy (FCM-PEIT): newly developed clinical useful method for injecting ethanol into nodules of hepatocellular carcinoma].
abstract: We have performed fluoroscopic contrast medium percutaneous ethanol injection therapy (FCM-PEIT) total 266 times to 82 hepatocellular carcinoma (HCC) nodules in 44 HCC cases: FCM-PEIT is the newly developed method that HCC nodules are punctured by a needle and injected with ethanol mixed with water-soluble contrast medium (Iopamidol containing 370 mg/ml iodine) (vol/vol: 7/3) under the fluoroscopic observation as well as ultrasonic diagnostic equipment (US). Autopsy analyses have demonstrated nearly complete tumor necrosis by FCM-PEIT. We analyzed the detectable rate (%) of the contrast medium-mixed ethanol (CME) leakage out of HCC nodules by US-alone, fluoroscope-alone, and US-fluoroscope observation. The detectable rate of the leakage was 63% by US-fluoroscope, while was only 32% by US-alone. Particularly, all leakages into intra hepatic bile duct were missed by US-alone. The maximal CME-amount for injection without any leakage was not uniform and not related to the size of HCC nodules. The present results suggest that FCM-PEIT is clinically more useful method for the treatment of HCC compared to general PEIT that HCC nodules are injected with ethanol under the US-alone observation, since it is easy to confirm whether ethanol can be sufficiently injected into HCC nodules without any leakage.
authors.affiliation: Department of Internal Medicine (I), Daisan Hospital, Jikei University School of Medicine.
authors.forename: K
authors.initials: K
authors.lastname: Komiyama
authors.forename: Y
authors.initials: Y
authors.lastname: Takekuma
authors.forename: T
authors.initials: T
authors.lastname: Nekohashi
authors.forename: T
authors.initials: T
authors.lastname: Abe
authors.forename: J
authors.initials: J
authors.lastname: Satoi
authors.forename: A
authors.initials: A
authors.lastname: Kanesaki
authors.forename: T
authors.initials: T
authors.lastname: Ui
authors.forename: S
authors.initials: S
authors.lastname: Morimoto
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003287:Contrast Media / Q000008:administration & dosage*; D000431:Ethanol / Q000008:administration & dosage*; D005471:Fluoroscopy; D006801:Humans; D015552:Injections, Intralesional; D007479:Iopamidol / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014463:Ultrasonography
chemical_list: D003287:Contrast Media; D000431:Ethanol; D007479:Iopamidol